Standard Operating Procedures
For
Enhanced Meningitis Surveillance in Africa

Version August 2009

Standard Operating Procedures for Enhanced Meningitis Surveillance in Africa
TABLE OF CONTENT

ACKNOWLEDGEMENTS .......................................................................................................................... 3
1. BACKGROUND .................................................................................................................................... 4
2. OBJECTIVES ....................................................................................................................................... 5
  2.1 General objective .......................................................................................................................... 5
  2.2 Specific Objectives ....................................................................................................................... 5
3. DEFINITIONS ...................................................................................................................................... 6
  3.1. Case definitions.......................................................................................................................... 6
        3.1.1. Suspected meningitis case ............................................................................................... 6
        3.1.2. Probable meningitis case ............................................................................................... 6
        3.1.3. Confirmed meningitis case ............................................................................................ 6
  3.2. Epidemiological thresholds ........................................................................................................ 6
        3.2.1. Alert threshold ................................................................................................................. 6
        3.2.2. Epidemic threshold .......................................................................................................... 7
4. METHODOLOGY .............................................................................................................................. 7
  4.1 Enhancing Meningitis Surveillance ............................................................................................... 7
      Early detection of meningitis outbreaks and prompt laboratory confirmation of circulating pathogens depend on effective implementation of surveillance activities at all levels.............7
  4.1.1. Pre-epidemic phase ............................................................................................................. 8
  4.1.2. Epidemic phase .................................................................................................................... 9
  4.1.3. Post-epidemic phase .......................................................................................................... 10
  4.1.4. Inter-epidemic phase ......................................................................................................... 11
  4.2. Data management...................................................................................................................... 11
        4.2.1 Data collection and transmission ..................................................................................... 11
        4.2.2. Data entry ....................................................................................................................... 12
        4.2.3. Data analysis .................................................................................................................. 13
  4.3 Specimen collection, storage, transportation and processing .................................................. 13
        4.3.1 Sample Collection .......................................................................................................... 14
        4.3.2 Utilisation of TI bottles .................................................................................................... 15
        4.3.3 Transportation of CSF specimen ...................................................................................... 15
        4.3.4. Specimen processing .................................................................................................... 15
5. CRITERIA FOR VACCINE CHOICE .......................................................................................... 17
6. CASE MANAGEMENT ..................................................................................................................... 18
7. COMMUNICATION .......................................................................................................................... 18
8. RESEARCH ...................................................................................................................................... 18
9. MONITORING AND SUPERVISION .......................................................................................... 18
  9.1 District level ................................................................................................................................ 18
  9.2 Regional / Provincial level ......................................................................................................... 19
  9.3 National Surveillance Unit ......................................................................................................... 19
  9.4 National Reference Laboratory ............................................................................................... 20
  9.5 National Technical Coordinating Group .................................................................................. 20
  9.6 WHO, Collaborating Centres and other Partners ..................................................................... 21
10. FEED BACK ................................................................................................................................... 21
ANNEX 1: PERFORMANCE INDICATORS FOR SOPs ................................................................. 23
ANNEX 2: Incidence thresholds for detection and control of epidemic meningococcal meningitis in highly endemic countries in Africa1 .............................................................. 24
ANNEX 3: WHO generic Case-based reporting form including clinical and laboratory information ................................................................................................................................. 25
ANNEX 4: WHO Generic Line List – for Reporting from Health Facility to District and for Use during Outbreaks .................................................................................................................. 27
ANNEX 5: Instructions on Using Trans-Isolate (TI) Bottles .......................................................... 29
ANNEX 6: Decisional tree for Bivalent (AC) or Trivalent (ACW) polysaccharide (PS) Vaccine use........................................................................................................................................... 31
ANNEX 7: ICG request forms ............................................................................................................ 32
ANNEX 8: List of participants at the Workshop to update SOP(s) .................................................. 39
ACKNOWLEDGEMENTS

As a surveillance tool and reference document, these standard operating procedures (SOPs) will allow the countries to orient health personnel at various levels of the health system on the implementation of the meningitis enhanced surveillance.; In other words, on what to do, in preparation of meningitis epidemics, during an epidemic, and all along the epidemic and inter epidemic seasons. Once learnt, the SOPs will allow health workers to detect early any epidemic outbreak, to rapidly confirm the causal pathogens by laboratory, undertake proper case management, and use the adequate vaccines in order to prevent further new cases or stop the spread of the epidemic.

I would like to sincerely thank all the participants at the 24 to 28 August 2009 Workshop in Bamako (Ref. list of participants in the annexes) who have at their most contributed to the revision of the current document. I would also thank all the persons below, for their much appreciated contributions and support in finalizing these SOPs: HQ: Dr William Perea; Dr Eric Bertherat; Dr Katya Fernandez. AFRO: Dr JB Roungou; Dr Adamou Yada; Dr F. Kveteminga Tshioko, Dr Celia Woodfill. IST/CA: Dr Matthieu Kamwa, Dr Mamadou Lamine Koné. IST/WA: Dr Fenella Avokey; Dr Adama Berthé; Pr. Denis Kandolo; Dr Fabien Diomandé; Mr Rodrigue Barry. MVP: Dr Marc LaForce; Dr Carol Tevi Benissan.

I would also like to invite all health workers in the countries of the meningitis belt and beyond to learn these guidelines for a high quality surveillance and response to meningitis epidemics.

The Coordinator
Inter country Support Team / West Africa

Dr Bokar Touré

For questions, comments, kindly refer to Dr Mamoudou H. Djingarey (djingareym@bf.afro.who.int) or Dr Sylvestre Tiendrebeogo (tiendrebeogos@bf.afro.who.int)
1. BACKGROUND

Epidemic meningococcal disease remains a major public health challenge in the African "meningitis belt", an area that extends from Senegal to Ethiopia with an estimated total population of 500 million. The estimated number of cases of meningitis for the last 15 years was more than 700,000 of whom about 10% died and more than 20% left with serious sequels. Epidemics in the meningitis belt are traditionally associated with Neisseria meningitidis serogroup A. However in 2002 Burkina Faso experienced the largest ever recorded meningitis epidemic due to serogroup NmW135, which was followed in 2003 by an outbreak with mixte aetiology (Neisseria meningitidis serogroup A and W135). In 2006 Neisseria meningitidis serogroup X was isolated as the cause of the outbreak in the districts of the western part of Niger, bringing in new threats for the meningitis belt countries.

During the 2001-2002 epidemic season, following the emergence of meningitis epidemics due to serogroup NmW135 from the 2000 pilgrimage in Saudi Arabia, WHO, in collaboration with its collaborating centres for meningitis, has progressively supported countries in implementing the strategy of enhanced surveillance of meningitis. Starting initially from three countries (Burkina Faso, Mali and Niger), the strategy is now actively being implemented in 14 countries of the meningitis belt (Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Côte d’Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Mali, Niger, Nigeria, Togo and Sudan).

Between 2003 and 2009, the 13 countries under enhanced surveillance of meningitis (Sudan excluded) reported to WHO more than 271 275 cases and 24 901 deaths due to meningitis. Out of 25481 CSF collected during the period, 9738 yield positive results. The repartition of causal pathogens is as follow: 58% Neisseria meningitidis A, 6% Neisseria meningitidis W135, 21% Streptococcus pneumoniae and 6% Hemophilus influenzae b.

Containing the epidemics on time and ensuring an adequate case management depend on accurate diagnostic of the disease and laboratory confirmation of the causal organism. Enhanced epidemiologic and laboratory surveillance enable
early detection of epidemics, identification of the serogroup in cause and the use of the appropriate vaccine to protect the population, thus preventing further spread of the disease, deaths or disabilities. When no vaccine is available, the control of meningitis epidemics will rely on enhanced surveillance, rapid and effective case management. This could happen when the country has no contingency stocks, or for serogroups for which no vaccine exists, or when the cost of the vaccine is unaffordable.

Lessons learnt from the implementation of the enhanced surveillance of meningitis highlight that putting in place adequate laboratory reagents, equipment and materials, training of health personnel as well as clear operating procedures are critical for the containment of meningitis epidemics.

Many of the selected countries have national plans for integrated disease surveillance and response (IDSR), which include meningitis. However there is a need for the surveillance systems to be strengthened in order to detect changing epidemiological patterns of meningitis epidemics in a timely manner and provide evidence to guide case management and prompt epidemic response. This is achieved only through an adequate funding of the epidemic preparedness and response plans.

The aim of these standard operating procedures is to guide health personnel from various levels of the health system in the implementation of enhanced surveillance of meningitis epidemics.

2. OBJECTIVES

2.1 General objective

To promptly detect, confirm, and respond appropriately to meningitis epidemics in the meningitis belt.

2.2 Specific Objectives

- To detect promptly meningitis cases from all health facilities
- To report systematically meningitis cases to the higher level
- To conduct rapid laboratory confirmation of causal pathogens
3. DEFINITIONS

3.1. Case definitions

3.1.1. Suspected meningitis case:
- Any person with sudden onset of fever (>38.5 C rectal or 38.0 C axillary) and one of the following signs: neck stiffness, altered consciousness or other meningeal signs.
- Any toddler with sudden onset of fever (>38.5 C rectal or 38.0 C axillary) and one of the following signs: neck stiffness, or flaccid neck, bulging fontanel, convulsion or other meningeal signs.

3.1.2. Probable meningitis case:
Any suspected case with macroscopic aspect of its CSF turbid, lousy or purulent; or with microscopic test showing Gram negative diplococcus, Gram positive diplococcus, Gram negative bacillus; or with leukocytes count more than 10 cells/mm3.

3.1.3. Confirmed meningitis case:
Isolation or identification of the causal pathogen (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus Influenzae b…) from the CSF of a suspected/probable case by culture, PCR or Agglutination test.

3.2. Epidemiological thresholds

3.2.1. Alert threshold (see Annexe 2)1:
For populations between 30,000 and 100,000 inhabitants: an attack rate of 5 cases per 100,000 inhabitants per week.2

---
1 For complementary criteria on alert and epidemic thresholds refer to: Detecting meningococcal meningitis epidemics in highly-endemic African countries. Weekly Epidemiological Record 2000, 75, 306-309
2 Attack Rate = (No of cases per week / population) x 100,000]
For populations less than 30,000 inhabitants: an incidence of 2 cases in one week or an increase in the number of cases compared to the previous non-epidemic years.

3.2.2. Epidemic threshold (see Annexe 2)¹:

For populations between 30 000 and 100 000 inhabitants: an attack rate of 15 cases per 100 000 inhabitants per week. When the risk of epidemic outbreak is high (no epidemic for the last 3 years, alert threshold reached early in the dry season) the recommended epidemic threshold is 10 cases per 100 000 inhabitants per week.

For populations less than 30 000 inhabitants: an incidence of 5 cases in 1 week or, the doubling of number of cases over a 3-week period.

4. METHODOLOGY

The surveillance system in the countries will be enhanced with particular emphasis on strengthening laboratory capacity for confirmation of causal agents. This will contribute to proper case management and appropriate choice of vaccine.

4.1 Enhancing Meningitis Surveillance

Early detection of meningitis outbreaks and prompt laboratory confirmation of circulating pathogens depend on effective implementation of surveillance activities at all levels. The level of preparedness and the public health measures for epidemic meningitis control varies throughout the year and should be intensified as the epidemic season approaches. During the epidemic season different procedures need to be established for districts that have crossed the alert and epidemic thresholds and those that have not. These procedures also vary depending on hyper endemic countries (within the meningitis belt) and other countries (outside the meningitis belt).
Therefore, for meningitis surveillance purposes, we will distinguish four different epidemiological phases: pre-epidemic, epidemic, post-epidemic and inter-epidemic. Specific procedures for data collection, specimen collection for laboratory confirmation will be indicated for each of these phases.

4.1.1. Pre-epidemic phase

This phase can be sub-divided into 2 phases: pre-alert and alert. 

**A district is in pre-alert phase**, when the weekly attack rate is below the alert threshold. All suspected cases need to be investigated and laboratory confirmed as they are recruited at health facility level. For any suspected case where a lumbar puncture is performed, a case-based form should be filled and the CSF sent to the nearest reference laboratory for bacteriological tests. Treat every single meningitis case with recommended antibiotics according to the national treatment protocols. Start the presumptive antibiotic treatment without delay, as soon as the CSF is collected, and before the laboratory results are out.

For each **district in alert phase**, detailed data on the suspected cases should be recorded on a line list. CSF sample collection should be strengthened and samples sent to the nearest reference laboratory for bacteriological tests. It is recommended to get at least ten (10) *Neisseria meningitidis* positive samples. This will help in making a rapid decision as to the type of vaccine to be used in case the district reaches the epidemic threshold, as well as orienting the clinicians for an effective case management. Hence, it is important to strengthen laboratory capacities at district levels to perform Gram stain, and regional levels to perform culture.
For every district in alert phase, do the following in box 1 below:

**Box 1: What should be done during the alert phase:**

1. Alert immediately the health officers in the next higher level.
2. Record cases on a line listing form with: residence, age, sex, vaccination status, outcome, laboratory results etc.
3. Collect and send specimens immediately to the nearest reference laboratory for bacteriological analysis and determination of causal pathogen. Be sure that samples are labelled with patient ID and have an IDSR case based form filled.
4. Confirm at least 10 positive samples for Neisseria meningitidis per surveillance unit (district or sub-district) for decision making about the appropriate vaccine to be used.
5. Samples should be sent using adequate media: TI bottles (for culture) and cryotubes for PCR.
6. Continue data analysis, graphing and mapping.
7. Treat all suspected cases with antibiotics as recommended by the national treatment protocol.

**Note:** Action thresholds were developed for the African meningitis belt countries. The situation in the other countries should be analyzed based on previous experience and on a case by case basis.

For countries outside the meningitis belt (non-endemic countries), suspected cases of meningitis in a district/sub-district, should be sampled whenever possible for laboratory confirmation of causal pathogens and antibiotic sensitivity. The predominance of Neisseria meningitidis among the isolated germs indicates the risk of a meningitis outbreak. This will allow implementing prompt response measures (adequate vaccine and antibiotic choice).

### 4.1.2. Epidemic phase:

A district is in epidemic phase when the attack rate reaches the epidemic threshold. For districts with large populations (above 100,000 inhabitants), it is recommended to calculate the weekly attack rates by sub-districts (surveillance zones or health facility catchment’s area) of 30,000 to 100,000 inhabitants in order to detect localized epidemics. As soon as the epidemic threshold is reached in a district or sub-district, it is recommended to conduct mass immunization campaign targeting the entire district, using the appropriate polysaccharide bivalent (AC) or trivalent (ACW) vaccine, and immunize all 2-30 years old population of the district. It is also recommended to vaccinate any contiguous district in alert phase.

Continue collecting CSF and sending samples to the reference laboratory to monitor the characteristics of the causal pathogens (serogroups, antibiotic sensitivity). Box 2 below summarizes the specific actions recommended during the epidemic phase:
Box 2. What should be done during the epidemic phase:

1. Vaccinate immediately the epidemic district with the appropriate vaccine as well as any contiguous district in alert phase.
2. Continue data collection, transmission and analysis.
3. Maintain regular collection of 5 to 10 CSF specimen per week throughout the epidemic season in the epidemic districts in order to detect any serogroup shift.
4. Treat all case with the appropriate antibiotic as recommended by the National protocols.

For longitudinal surveillance purposes, regular collection of at least 5 to 10 CSF samples will be maintained in all epidemic districts for monitoring the circulating serogroups, antibiotic susceptibility testing, as well as any serogroup shift during the epidemic period.

A Rapid Response Team (RRT) from central or regional/provincial level should be sent to the affected areas to support surveillance and laboratory activities. The team should evaluate the data collection, analysis and transmission, as well as lumbar puncture practices, the use of trans-isolate medium and all laboratory procedures (e.g., Gram stain, cytology, latex agglutination tests, etc).

Note that before sending a specimen to the reference laboratory, it should be adequately labelled using the IDSR case-based form.

Box 3 below describes the process for requesting vaccine from ICG:

Box 3: Request to ICG for vaccine procurement

- As soon as the epidemic threshold is reached in a district, the country should vaccinate the district using the vaccines from the contingency stocks. At the same time, in order to replenish the stock, a request should be sent through WHO country office to the International Coordinating Group (ICG) for meningococcal vaccine provision. The ICG is composed of WHO, UNICEF, MSF and IFRC. The information below are key in order for ICG members to accept a country's request:
  - The epidemiological situation per district per week
  - The repartition of attack rates by age groups
  - The identification of causal pathogens by district.
  (See ICG request forms in annexe 7)

4.1.3. Post-epidemic phase

The post epidemic phase corresponds to the first 4 weeks after the end of an epidemic. The end of a meningitis epidemic is declared when the attack rate in the last epidemic district descends below the alert threshold for two consecutive weeks. During this phase it is recommended to:
• Evaluate the response/management of the epidemic to outline the gaps, lessons learnt and make recommendations for a better control of future meningitis epidemics.
• Conduct an external evaluation (all the system, vaccine coverage survey) These evaluations are conducted in order to draw lessons and make recommendations for a better control of future epidemics. Adequate resources should be mobilized to conduct these evaluations.

4.1.4. Inter-epidemic phase

The inter-epidemic phase extends from the end of an epidemic season to the beginning of the next season. In this phase the epidemic profile of the causal pathogens may be different from the epidemic phase. Therefore, the identification of prevailing germs is important to better understand and guide future control of meningitis epidemics in Africa. During this phase it is recommended to:

• Establish a strong collaboration among the surveillance officers, clinicians and the national reference laboratory officers in order to undertake a comprehensive sample collection and confirmation mechanism.
• Continue surveillance and laboratory confirmation of suspected meningitis cases in all the national, regional and district hospitals.

4.2. Data management

4.2.1 Data collection and transmission

For all suspected meningitis cases, some basic patient information will be collected using the IDSR Line List form (See annex 4).

The suspected cases and deaths should be recorded and transmitted weekly to the district surveillance officer. Data should be immediately compiled and transmitted either by radio, telephone/SMS, fax, email (or the quickest means available) to provincial and national levels. Weekly notification should be done throughout the season/year. Districts should report weekly, even when no cases are recorded (“Zero reporting”).

Moreover, in case of epidemics, the reporting of cases and deaths can be done on a daily basis.
The line list should be completed at the health facility level, compiled at district level and a copy sent to the regional and national levels, on a weekly basis. For each suspected meningitis case with CSF specimen, fill an IDSR case-based form (Annex 3). Provide a unique identifier (Epid Number: Countrycode(3 letters)-Provincecode(3 letters)-Districtcode(3 letters)-Yearcode(2 digits)-CaseNumber(4 digits): CCC-PPP-DDD-YY-NNNN) to link the laboratory results with the patient clinical/epidemiological records. Keep a copy of the IDSR case based form at the district level, and send the other copy together with the CSF specimen to the national reference laboratory. This Epid Number is given by district level.

4.2.2. Data entry

4.2.2.1. At district level

The line lists sent by peripheral health facilities to the district will be entered into a computer programme (Excel preferably or Epi Info) by the district surveillance officers. They will also enter the laboratory data and tests results on the same software. The completed data base will then be sent to the regional/national level on a weekly basis in case of epidemics, or on a monthly basis when there is no epidemic.

4.2.2.2. At regional level

A database similar to that of the level district will be made available at the regional laboratory. The data bases received from the districts will be merged by the regional surveillance officer into a single database using preferably Excel software (or Epi Info), and sent to the national level on a weekly basis during epidemics or on a monthly basis when there is no epidemic. When patients are directly seen at the regional hospital without being referred by a district, the laboratory results produced by the regional hospital will also be entered by the epidemiologist at the regional hospital using Epid-number. He should contact his counterpart of the district of origin of the patient who will allocate an Epid Number to each patient. This interaction is crucial in order to avoid double entries.
4.2.2.3. At central/national level

The data bases received from the regions or districts will be merged into a single national database using preferably Excel (or Epi Info), before sending it to WHO and partners on a weekly basis during epidemics and on a monthly basis when there is no epidemic.

4.2.2.3. At the national reference laboratory

The data from the national reference laboratories will be computerized using Excel or Epi Info, then sent to the national surveillance/epidemiology unit, where they will be linked to the clinical data using the Epid-number. The results will then be sent to the regions and districts where the specimen came from.

The data manager at the national surveillance unit should check for data entry flaws and clean the data base on a weekly basis. He should make sure that clinical and laboratory data of each patient are linked, before any detailed data analysis.

4.2.3. Data analysis

The disease surveillance officers at each level should analyse their data. The supervisors at regional and national levels should ensure that all districts keep an up-to-date weekly epidemic trend (curve) of meningitis cases with the alert and epidemic thresholds shown. Every week, the data manager of the national Surveillance Unit should make a standard map showing the alert and epidemic districts, as well as the laboratory results by district and for the country.

4.3 Specimen collection, storage, transportation and processing

Before the beginning of the epidemic season, each country should:

- Procure an adequate stock of lumbar puncture kits, Rapid latex kits (Pastorex), anti sera (monovalent), Trans-isolate (TI) media, cryotubes, and triple packaging box for specimen transport.
• Preposition these materials at provincial and district levels under the responsibility of the provincial and district disease surveillance and laboratory officers.

**Note:**

- TI media should be stored and used according to the manufacturer's guidelines (see Annex 5 for instructions on using TI media).
- Depending on the epidemic situation and resources available, WHO and/or other technical and financial partners, may supply the countries with TI media and other laboratory consumables on a case-by-case basis.

### 4.3.1 Sample Collection

Health personnel or Rapid Response Teams on the field should systematically collect CSF specimens for laboratory confirmation before the commencement of antibiotics therapy. It is estimated that 20 to 30 CSF samples per district are sufficient to determine the circulating causal pathogens and guide the choice of the appropriate vaccine (AC or ACW). Ensure that at least 10 of the samples collected are positive for *N. meningitidis* for a better decision on the situation in a district. If not, collect more samples from that district. Perform antibiotic susceptibility testing to guide the use of appropriate antibiotic for case management. The quicker these samples are obtained at the reference laboratory the better.

Once an epidemic has been declared in a district, regular collection of CSF specimens should be maintained in that district throughout the epidemic season, in order to monitor circulating pathogens. However the systematic collect of CSF from each patient is not recommended. The number of CSF to be collected per week should be 5-10 per district.

Health personnel at health facility should be trained on lumbar puncture technique, specimen collection, TI utilisation, handling and transportation to the reference laboratory. The laboratory technicians should be trained on how to perform Gram stains, rapid latex agglutination using Pastorex kits, or dipsticks.
4.3.2 Utilisation of TI bottles

The TI bottles are stored between 4°C and 8°C in the refrigerator. Before using a TI bottle, it will be sorted and kept at room temperature 30 minutes before adding the CSF. From each suspected meningitis case, 1 ml of CSF should be injected aseptically into a TI media. After the CSF has been injected, the TI medium should be vented and kept at room temperature away from direct sunlight or dust. The inoculated TI medium should not be refrigerated (see Annex 5 for instructions on using TI media).

4.3.3 Transportation of CSF specimen

For culture:
The inoculated TI medium should be sent from the health facility to the district within 24 hours. The district should send the inoculated TI media to the national/state reference laboratory at least twice a week. Inoculated TIs are sent without venting needle and without ice packs. Once inoculated, TI media should be kept at room temperature.

For PCR (Polymerase Chain Reaction):
One (1) to two (2) ml of CSF should also be collected in cryotubes and sent along with TIs, for PCR testing. Unlike inoculated TI media, cryotubes should be refrigerated or freezed during storage and transported to the reference laboratory under reverse cold-chain system. PCR can detect etiological pathogens even where there was no growth from the specimens sent by TI.

4.3.4. Specimen processing

The identification of causal pathogen is essential to confirm the nature of the meningitis epidemic and institute control measures. Therefore, laboratory confirmation of suspected meningitis cases should be a standard practice during the meningitis epidemic season. The following laboratory tests should be conducted depending on the health services or organisational levels (national, regional, district) and the technical capacity of the laboratory at that level:
o Gram stain and cell counts at district laboratory or health facility with appropriate equipment

o Rapid latex tests at district laboratory level. (Note that the use of a latex test (Pastorex®) capable of identifying Nm W135 is highly recommended during the initial phase of an outbreak. Pastorex can be used at field level and substantially reduce the delay for bacteriological confirmation and decision making).

o Culture and serogroup at national or regional reference laboratories.

o Antibiotic susceptibility pattern should be conducted for all specimens received at national reference lab.

o DNA detection: Polymerase Chain Reaction (PCR): at national level to confirm the causal agent by biomolecular (DNA) test. PCR can be used to confirm the germ on negative TI (no growth by culture). Note that several countries in the region now have access to PCR. For PCR testing, CSF specimens could be stored in cryotubes preferably in a freezer (-20°C) or in sterile dry tubes in the refrigerator (+4°C) for some weeks, and shipped in a cool box to national or regional reference laboratory.

4.3.5. Turn-around time of laboratory results:

The laboratory results should be sent by the CSM laboratory focal officers to the highest level and to the facility that sent the sample(s) within 48 hours upon completion:

- Districts: within 48 hours upon reception of the sample(s)
- Province/Region: within 5 days upon reception of the sample(s)
- National level: within 7 days upon reception of the sample(s)

4.3.6. Quality control and sequence-type

For quality control and sequence-type, 10 to 20% of isolates obtained at national level should be regularly sent to WHO collaborating centres5 (Marseille, Oslo,  

---

5 - Institut de Médecine Tropicale du Service de Santé des Armées, IMTSSA - Le Pharo BP 46, Marseille, 13998 Armées Marseille, France, Tel. +33 4 91 15 01 15, Fax +33 4 91 59 44 77, e-mail: imtssa.meningo@free.fr
Atlanta) for genotypic characterization. This will allow monitoring epidemiological trends of serogroups and genotypes and a better understanding of the spreading patterns of Nm epidemic complexes in the African region.

5. CRITERIA FOR VACCINE CHOICE

The decision on the type of vaccine to be used (See Decisional Tree in Annex 6) should ideally be based on the results from at least 10 Nm positive specimens.

In order to obtain that number of Nm positive specimens, it is estimated that 20 to 30 CSF specimens should be collected from the affected area.

Efforts should be made to collect and test CSF specimens in the field as early as possible.

The proportion of Nm W135 required warranting the use of ACW trivalent vaccine could be defined according to the number of Nm positive samples available from a given affected area.

The following criteria could be suggested:

\[
\begin{align*}
& \geq 30\% \text{ of W135 out of 10-19 Nm positive samples} \\
& \text{OR} \\
& \geq 20\% \text{ of W135 out of 20 or more Nm positive samples.}
\end{align*}
\]

In the total absence of laboratory evidence of Nm W135 the use of trivalent ACW vaccine should be strongly discouraged.

In the above-mentioned situation, vaccination with bivalent AC vaccine should be recommended (provided that some laboratory evidence of Nm A is available).

In situations where a full blown epidemic is reported and where the minimum percentage of Nm W135 was not reached, the identification of one or more Nm W135 in the concerned area(s) and concurrent W135 epidemic in contiguous area(s) will justify the use of the trivalent vaccine.
In any other situation, decisions to use vaccine, should be evaluated on a case-by-case basis and should take into account all epidemiological and laboratory information available in the country.

6. CASE MANAGEMENT

Treat all cases of meningitis as quickly as possible, using the adequate antibiotics and according to the national treatment protocols. If a lumbar puncture is to be performed, do so before the antibiotic treatment. Treat the patient with presumptive antibiotic without waiting for the laboratory results.

7. COMMUNICATION

The following communication strategies should be implemented at all levels:
- Advocacy
- Social mobilization
- Communication for behaviour change
Key sensitization messages should be broadcast for an early treatment seeking by patients.

8. RESEARCH

Research topics should be identified according to countries priorities. Resources should be mobilized to conduct key operational researches and the results used for improving the control of epidemic meningitis in Africa.

9. MONITORING AND SUPERVISION

9.1 District level

The District Medical Officer will ensure during supervisory activities that the personnel of health facilities have been fully briefed on the process. For health facilities known at risk of meningitis epidemics, the personnel should be trained on Lumbar puncture techniques as well as how to handle and transport CSF specimens. Train also the health personnel on the proper case management, on alert and epidemic thresholds as well as data analysis and reporting using appropriate IDSR forms.
The Epidemic Management Committee (EMC) of the district should be reactivated (if not functioning) for decision making and better management of the situation. Regular weekly meetings are advised.

9.2 Regional / Provincial level

Surveillance officers at regional level should help to conduct and supervise enhanced Epidemic Meningitis Surveillance at district levels. The other focal points for the surveillance of vaccine preventable diseases (polio, measles and yellow fever) will be called in support for enhanced meningitis surveillance. Resources from AFP will be of great input (logistics) for enhancing the meningitis surveillance in line with the IDSR strategy.

The surveillance officer at regional/provincial level should set up a mechanism to monitor districts in alert or epidemic phases. He should make sure that CSF is collected for laboratory confirmation, and whether samples from districts in alert or epidemic phase have been sent to the national or regional laboratory, as well as the return of laboratory results.

The Epidemic Management Committee at provincial level should be reactivated (if not functioning) for decision making and better management of the situation. Regular weekly meetings are advised. Supervision and monitoring of the situation should be conducted to support the districts Continuous supportive supervision from the National level is necessary at this stage.

9.3 National Surveillance Unit

Each week during the Epidemic season, the national surveillance officer should monitor if any districts have reached the alert threshold, and check with the laboratory if TI media (CSF samples) have started arriving from that district, otherwise, means of supporting the district for laboratory confirmation should be sorted out without delay.

Other important activities to be conducted at this level:
- Vaccine supply,
- Drugs supply,
- Provision of data management tools,
- Evaluation of monitoring indicators.

*The National Epidemic Management Committee (EMC) should* be reactivated for situational analysis, recommendation of proper control measures and better management of the situation. Regular weekly meetings should be conducted to analyse the epidemiological and laboratory data, upon which, supervision and monitoring actions are decided to support the regions and districts. The national EMC should also advocate for resource mobilisation (funds, drugs, laboratory reagents, vaccines and logistics).

*A rapid response team (RRT)* should be designated at national level including partners for field investigation and rapid implementation of control measures. For the composition of the EMC and RRT refer to the IDSR guidelines and MoH documents on the matter.

**9.4 National Reference Laboratory**

The Director of the National Reference Laboratory (NRL) through the CSM laboratory focal officer should ensure that high-quality testing of CSF specimens in the laboratory and results are sent promptly to districts. He should provide regular feedback on samples collected and processed, in order to minimise contamination and handling/transportation problems. He should organise regular training and supervision of provincial and district laboratories, and ensure that reagents and laboratory equipment are available. He should also ensure that 10 to 20% of positive isolates are transported to WHO Collaborating Centres for QA/QC (in accordance with international standards) and for genotyping and sequence-typing.

**9.5 National Technical Coordinating Group**

In each country a national co-ordinating body comprising the head of the National Surveillance Unit, the Head of National public health Laboratory and the WHO Disease Prevention and Control Officer (DPC) will be put in place. This group will monitor through weekly meetings the implementation of activities related to enhancing the Meningitis surveillance.
The group will ensure that partners contribution are taken into account and all activities are well co-ordinated. This group is responsible for regular updates on surveillance activities as well as the final evaluation report on the country’s response to epidemics.

The members of this coordinating body will be orientated on the implementation of enhanced surveillance of meningitis.

Members of the coordinating group are the core members of the national epidemic management committee.

9.6 WHO, Collaborating Centres and other Partners

At Country level, support for these activities will be co-ordinated by the Disease Prevention and Control Officer (DPC) under supervision of the WR.

At sub-regional level, WHO with its collaborating centres and other partners will provide technical, financial and logistics support to countries.

10. FEED BACK

Reports, bulletins, annual statistical reports, websites etc… will be used as feedback tools.
ANNEXES
ANNEX 1: PERFORMANCE INDICATORS FOR SOPs

1) **Reporting**: Percent (%) of districts that have reported weekly meningitis cases and deaths on time. **Target**: 80% of districts.

2) **Investigation-Field**: Percent (%) of alert or epidemic districts which have been investigated and documented within the 48 hours after reaching the alert or epidemic threshold. **Target**: 80%

3) **TI transportation**: Percent (%) of districts in alert or epidemic phase that have sent at least 10 TI bottles to the national reference after reaching the alert threshold. **Target**: 80% of alert or epidemic districts.

4) **Laboratory - Confirmation**: Percent (%) of epidemic districts that have confirmed the serogroup of at least 10 suspected meningitis cases within 7 days of surpassing the alert or epidemic threshold. **Target**: 80% of alert and epidemic districts.

5) **Feedback-Lab**: Percent (%) of alert and epidemic districts that have received results from the samples sent to the national reference laboratory within 7 days of receiving the TIs by the laboratory. **Target**: 80% of districts sending TI bottles.

6) **Negative specimen**: Percent (%) of culture-negative samples among samples received per week by the reference laboratory. **Target**: < 20% of samples during the week.

7) **Contaminated specimen**: Percent (%) of contaminated samples among samples received per week by the reference laboratory. **Target**: < 20% of samples received during the week.

8) **Reporting to WHO**: Percent (%) of countries which have reported on time weekly data (surveillance and laboratory results) to WHO. **Target**: 80% of countries.

9) **Feedback**: Percent (%) of weekly meningitis bulletins produced by WHO (and sent to countries, WHO/AFRO/HQ and partners). **Target**: 80% timeliness.
## ANNEX 2: Incidence thresholds for detection and control of epidemic meningococcal meningitis in highly endemic countries in Africa

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alert threshold</strong></td>
<td>Over 30,000</td>
</tr>
<tr>
<td>Inform authorities</td>
<td>• 5 cases / 100,000 inhabitants / week</td>
</tr>
<tr>
<td>Investigate</td>
<td>Or</td>
</tr>
<tr>
<td>Confirm</td>
<td>• An increase in the number of cases compared to previous non-epidemic years</td>
</tr>
<tr>
<td>Strengthen surveillance</td>
<td></td>
</tr>
<tr>
<td>Prepare</td>
<td></td>
</tr>
</tbody>
</table>

**Epidemic threshold**

| Mass vaccination | Over 30,000 | Under 30,000 |
| Distribute treatment to health centres | • 15 cases / 100,000 inhabitants / week | • 5 cases in one week |
| Treat according to epidemic protocol | Or if there has been no epidemic for three years and if vaccination coverage is < 80% | Or |
| Inform the public | • 10 cases / 100,000 inhabitants / week | • Doubling of the number of cases in a three-week period |
| | | Or |
| | | • Other situations should be studied on a case-by-case basis |

If there is a meningitis epidemic in a neighbouring area

- the alert threshold becomes the epidemic threshold

2. Other epidemic risk factors: reaching the alert threshold early in the dry season; poor vaccine coverage or last mass immunization campaign > 3 years; high population density.
3. For example, week 1: 1 case, week 2: 2 cases, week 3: 4 cases.
4. For mass gatherings, refugees and displaced persons, two confirmed cases in a week should prompt mass immunization campaign in this population.
**ANNEX 3: WHO generic Case-based reporting form including clinical and laboratory information**

<table>
<thead>
<tr>
<th>Reporting Health Facility</th>
<th>Reporting District</th>
</tr>
</thead>
</table>

**Generic Reporting Form – from Health Facility/Health Worker to District Health Team**

<table>
<thead>
<tr>
<th>Disease</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AFP</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Cholera</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Diarrhea with Blood/Shigella</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Dracunculiasis</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Neonatal Tetanus</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Measles</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Meningitis</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Plague</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Viral Hemorrhagic Fever</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Yellow Fever</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Other</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

**Assigned by District:**

<table>
<thead>
<tr>
<th>EPID N°:</th>
<th>Province</th>
<th>District</th>
<th>Year</th>
<th>Case N°</th>
<th>Date received at regional level</th>
<th>Date received at National lab</th>
</tr>
</thead>
</table>

**Name(s) of Patient:** __________________________

**Age:**

- (If DOB unknown) (NNT only)
- (If <12 months)
- (DOB years months days)

**Sex:** M=Male F=Female

**Patient’s Residence:** Village/Neighborhood __________________________

**Town/City:** __________________________

**Date of Birth:** ____/____/____

**Location of Residence:** __________________________

**U=Urban R=Rural**

**U=Urban R=Rural**

**Locating Information:**

If applicable, Name of mother and father

If neonate or child

**Date Seen at Health Facility:** ____/____/____

**Date at Health Facility Notified District:** ____/____/____

**Dates of Onset:** ____/____/____

**Date of last vaccination:** ____/____/____

**Number of vaccine doses received**

- Measles, TT, YF documented by card. For Meningitis, history.

**In/Out Patient:** 1=In-patient 2=Out-patient

**Outcome:** 1=Alive 2=Dead 9=unknown

**Final Classification:** 1=Confirmed 2=Probable/Compatible 3=Discarded 4=Suspected

**Person Completing Form:** Name: __________________________

**Signature:** __________________________

**Date Sent Form to District:** ____/____/____

**email/phone No.: __________________________**
### If Laboratory Specimen Collected

**For Health Facility:** If laboratory specimen is collected, complete the following information. Send a copy of this form to the laboratory with the specimen.

- **Date of specimen collection:** _____/_____/_____
- **Specimen source:** Stool  Blood  CSF
- **Date Specimen sent to lab:** _____/_____/_____

**For the Lab:** Complete this section and return the form to district team and clinician.

- **Date laboratory specimen:** _____/_____/_____
- **Specimen Condition:** Adequate  Not adequate

<table>
<thead>
<tr>
<th>Disease/Condition</th>
<th>Type of test</th>
<th>Results (P=pending)</th>
<th>Disease/Condition</th>
<th>Type of test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholera</td>
<td>Culture</td>
<td>+ - P</td>
<td>Yellow Fever</td>
<td>IgM</td>
<td>+ - P</td>
</tr>
<tr>
<td></td>
<td>Direct Exam</td>
<td>+ - P</td>
<td>Measles</td>
<td>IgM</td>
<td>+ - P</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rubella</td>
<td>IgM</td>
<td>+ - P</td>
</tr>
<tr>
<td><strong>Meningitis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N. meningitidis</td>
<td>Culture</td>
<td>+ - P</td>
<td>RVF</td>
<td>IgM</td>
<td>+ - P</td>
</tr>
<tr>
<td>S. pneumonia</td>
<td>Culture</td>
<td>+ - P</td>
<td>Ebola</td>
<td>IgM</td>
<td>+ - P</td>
</tr>
<tr>
<td>H. influenza</td>
<td>Culture</td>
<td>+ - P</td>
<td>CCHF</td>
<td>IgM</td>
<td>+ - P</td>
</tr>
<tr>
<td>N. meningitidis</td>
<td>Latex</td>
<td>+ - P</td>
<td>Lassa</td>
<td>IgM</td>
<td>+ - P</td>
</tr>
<tr>
<td>S. pneumonia</td>
<td>Latex</td>
<td>+ - P</td>
<td>Marburg</td>
<td>IgM</td>
<td>+ - P</td>
</tr>
<tr>
<td>H. influenza</td>
<td>Latex</td>
<td>+ - P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shigella</td>
<td>Culture</td>
<td>SD type 1 Other shig</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysenteriae</td>
<td></td>
<td>shig</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plague</td>
<td>Culture</td>
<td>+ - P</td>
<td>IFA&gt;1: 64</td>
<td>+ - P</td>
<td></td>
</tr>
</tbody>
</table>

**Other laboratory results:**

- ____________________________
- ____________________________
- ____________________________
- ____________________________

**Date laboratory sent results to district:** _____/_____/_____

**Name of laboratory sending results:** ____________________________

**Other pending tests:**

- ____________________________
- ____________________________
- ____________________________

**Date laboratory results sent to clinician by district:** _____/_____/_____

**Note:** District is responsible for ensuring laboratory results get to clinicians. Failure to do so will undermine cooperation with clinicians on reporting of cases in the future.
## ANNEX 4: WHO Generic Line List – for Reporting from Health Facility to District and for Use during Outbreaks

<table>
<thead>
<tr>
<th>EPID Number (CCC-PPP-DDD-YY-NNNN)</th>
<th>(O)ut / (I)n Patient</th>
<th>Name</th>
<th>Village or Town and Neighbourhood</th>
<th>Sex</th>
<th>Age</th>
<th>Date seen at health facility</th>
<th>Date of onset of disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Generic Line List (Continued)

<table>
<thead>
<tr>
<th>Immunization status (specify vaccine type)</th>
<th>Blank variable</th>
<th>Blank variable</th>
<th>Laboratory Tests</th>
<th>Outcome (A)live (D)ead</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen taken (Yes/No) If yes, date collected</td>
<td>Laboratory results</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1)  
(2)  
(3)  
(4)  
(5)  
(6)  
(7)
ANNEX 5: Instructions on Using Trans-Isolate (TI) Bottles

How to use the Trans-Isolate (T-I) system for isolation and transport of meningococci and other agents causing bacterial meningitis from CSF

1. Procedure for inoculating T-I medium for transporting meningococci and other agents causing bacterial meningitis from CSF:

   1.1 Remove a vial of Trans-Isolate (T-I) medium from refrigerator at least 30 minutes before inoculating it with the specimen. Allow the vial to warm to room temperature which is more favourable for growth of the organism.

   1.2 Before inoculating the vial, check to see if there is any visible growth or turbidity. If there is visible growth or turbidity, discard the vial, because it may be contaminated.

   1.3 Lift up the small lid in the middle of the metal cap on top of the T-I vial.

   1.4 Disinfect the top of the T-I vial with 70% alcohol or iodine. Allow to dry (usually 30 to 60 seconds).

   1.5 Use a sterile syringe and sterile needle preferably 21G, 0.8 mm. to aspirate 500 microliters (one-half of an ml) of cerebrospinal fluid (CSF) from the tube containing CSF.

   1.6 Inject the CSF into the T-I vial through the disinfected dry stopper on the top of the T-I vial.

2. Transport and incubation of T-I vials, and inoculation of the culture media

   The procedures to follow depend upon how promptly the TI vials can reach the laboratory of reference that will perform culture and isolation.

   If T-I vials cannot reach the laboratory of reference within 24 hours:

   - Label the T-I vial with the date, name of the patient, and any other necessary identifiers.
   - Ventilate the T-I vial with a sterile cotton plugged needle. The Needle should not dip into the culture media (broth).
• Store the ventilated T-I vial in an upright position at room temperature. Make sure it is away from excessive heat, direct sunlight, and dust.
• Before transporting the vial, remove the ventilating needle from the top of the T-I vial. This will prevent leakage and contamination during shipment.
• Transport the T-I vial in a sealed plastic bag to minimize the risks of contamination and attach the case report form.

If T-I vials can reach the laboratory of reference within 24 hours:

• Label the T-I vial with the date, name of the patient, and any other necessary identifiers.
• Ship the T-I vials without ventilation.
• Transport the T-I in a sealed plastic bag to minimize the risk of contamination and attach the case report form.

3. Additional recommendations about the proper use of T-I vials and ventilating the inoculated T-I vials:

• The T-I vials can be used for at least 1 year after the date of production provided that they are stored in the refrigerator.
• Freezing T-I vials destroys the T-I medium.
• Non-inoculated T-I vials should be packed in cold packs for shipment to the laboratory of reference.
• In previous studies (Ajello et al below), cultures on ventilated T-I vials 2 to 4 weeks after inoculation with CSF (from patients with acute bacterial meningitis), incubation and transport resulted in a loss of growth in only 20 to 25% of inoculated vials. Without ventilation the losses were much greater.
• Contamination is the single most problematic point with the system. Aseptic measures and understanding the risks are necessary to achieve good recovery of the isolates.

ANNEX 6: Decisional tree for Bivalent (AC) or Trivalent (ACW) polysaccharide (PS) Vaccine use

**Mainly Nm identified**

- **Laboratory test results available**
  - **Yes**
    - **Mainly Nm identified**
      - **In 10 or more samples**
        - W135 not identified
      - **In less than 10 samples**
        - W135 not identified
      - **W135 identified**
        - **At least one W135 identified**
          - W135 epidemic in a neighboring district
        - **W135 not identified**
          - AC PS
    - **Specimens obtained**
  - **No**
    - Conduct active field investigation and obtain specimens

**Epidemic threshold reached**

- **Yes**
  - **Laboratory test results available**
    - **Mainly Nm identified**
      - **In 10 or more samples**
        - W135 not identified
      - **In less than 10 samples**
        - W135 not identified
      - **W135 identified**
        - **At least one W135 identified**
          - W135 epidemic in a neighboring district
        - **W135 not identified**
          - AC PS
    - **Specimens obtained**
  - **No**
    - Conduct active field investigation and obtain specimens

**AC PS**

**ACW PS**

**AC PS**
**ANNEX 7: ICG request forms**

**INTERNATIONAL COORDINATING GROUP FOR MENINGITIS VACCINE PROVISION (ICG)**

**APPLICATION FORM TO ACCESS ICG SUPPORT**
(email: outbreak@who.int or fax to +41 22 791 4198)

The International Coordinating Group (ICG) on Vaccine Provision for Epidemic Meningitis Control is a partnership between UNICEF, MSF, IFRC and WHO established to ensure rapid and equal access to vaccines, injection materials and oily chloramphenicol, for emergency outbreak response as well as their optimal use when stocks are limited. The release of these emergency supplies constitute an advance to the countries in outbreak situation, as such their reimbursement is required to maintain ICG stockpiles at constant levels.

### General information

- **Date of Request:**
- **Country requesting:**
- **Region/State:**
- **Affected areas (town/district/division):**
- **Requesting agency:**
- **Name of person filling the form:**

### Vaccine reception information in the country/region

- **Name**
- **Tel.**
- **Fax**
- **Email**
- **Address**

**Reimbursement/Payment Information:**
- **Planned Funding source**
- **Name of Contact (if other than above)**
- **Email**

To activate the ICG process for meningitis vaccine and antibiotic distribution it is essential to provide the following documents (incomplete requests will delay assessment):

1. Essential information in the following forms (tick the box if attached):
   - **Meningitis emergency stockpile application form** (pages 2, 3 & 4)
   - **Annex 1: Epidemiological information** (excel sheet 1)
   - **Annex 2: Laboratory Information** (excel sheet 2)

2. **Vaccination plan by district**
   (Objective of mass vaccination, targeted zone, planned vaccination date, duration, number of teams, etc.
   See example attached.)
3. Spot map of the affected areas

Meningitis Emergency Stockpile Application Form

<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I. Epidemiological Information

Please include a relevant extract (affected areas and weeks) of the epidemiological national data base or fill out the excel data collection file in ANNEX 1.

Brief Summary:
Please describe when the epidemic threshold\(^3\) was crossed by the affected districts/sub-district (town, unit, payam, ward, etc) and the current evolution of this epidemic situation. If applicable also give relevant information for neighbouring districts having crossed the alert threshold.

II. Laboratory Information

Please fill out the excel data collection table in ANNEX 2 as well as the summary table below

Summary
How many specimens were tested in total (all methods included)? How many were positive?

<table>
<thead>
<tr>
<th>District/ division/town*</th>
<th>Number of specimen positive Nm A</th>
<th>Number of specimen positive Nm W135</th>
<th>Number of specimen for other Nm serogroup (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^3\) Epidemic threshold:
- Population greater than 30 000: an incidence of 15 cases per 100,000 inhabitants per week, in 1 week. However, when the epidemic risk is high (no epidemic for 3 years or alert threshold crossed early in the dry season), the recommended epidemic threshold is 10 cases per 100 000 inhabitants per week, in 1 week (see reference article for more details).
- Population less than 30 000: 5 cases in 1 week or doubling of the number of cases over a 3-week period (other situations must be evaluated in a case-by-case basis according to the epidemic risk).
- For operational purposes, when an epidemic is confirmed in a neighbouring area, the alert threshold also serves as the epidemic threshold.

III. Antibiotic Request

First line standardized treatment used:

Oily chloramphenicol requested to the ICG? Yes ☐ No ☐

Number of vials available

Number of vials requested 4

Is the treatment provided free of charge? Yes ☐ No ☐

IV. Vaccine Request

Age groups targeted for vaccination: from to years of age

Comments (as needed)

<table>
<thead>
<tr>
<th>District/ division/ sub-district/town 1</th>
<th>Week Alert 2</th>
<th>Week Epi 3</th>
<th>Total Population</th>
<th>Target population</th>
<th>Doses required 4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total

1 Please add rows if necessary

2 Calendar week when the alert threshold has been reached in this area

3 Calendar week when the epidemic threshold has been reached in this area

4 Note that the total number of vaccine doses needed is calculated with the following formula:
   Total required doses = number of target population x wastage factor (1.17)
   If reserve is needed, please indicate and provide justification

Type and number of doses of vaccine in stock and requested to control the epidemic

<table>
<thead>
<tr>
<th>Type of vaccine</th>
<th>Stock available (doses)</th>
<th>Doses requested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bivalent (A/C)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trivalent (A/C/W)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetravalent (ACYW135)*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Not available through the ICG

V. Vaccination material

Please note that according to WHO recommendations on injection safety, vaccines should be systematically bundled with syringes for administration and reconstitution of the vaccine, as well as safety boxes for their disposal. This policy does not imply that these items must be physically packaged together but that they must ultimately be made available in adequate quantities at the vaccination site or health facility in a timely manner. (http://www.who.int/injection_safety/toolbox/docs/en/Guiding_Principle_Inj.pdf).

These vaccination materials will be systematically sent by the ICG whenever vaccine is released, shipped by either air or by boat. Transport by boat will only be chosen if the necessary vaccination materials can be made available at the vaccination sites from in-country stocks. The country stocks will then be replenished by the ICG supplies. This will minimize the elevated packing and freight costs of sending these voluminous materials by air, however, delivery delays will be several weeks longer than air transport.

In order for the ICG to decide the mode of transport, please provide us information about the availability of auto-disable, reconstitution syringes, and incineration boxes in the country.

Auto disable syringes (0.5ml) Quantity available in country (in units)
Reconstitution syringes Quantity available in country (in units)
and needles (19G)
Incineration boxes (15L) Quantity available in country (in units)

VI. Technical Support

Please specify what type of support, if any is needed

VII. Reimbursement

In order to ensure the sustainability of the revolving stock, the ICG requires a pledge confirmation for replenishment of the stockpile and other supplies. The requesting country or agency is responsible for reimbursing the costs of vaccines, accompanying
injection materials (including incineration boxes, auto disable and reconstitution syringes and needles) and oily chloramphenicol. This includes the costs of packaging, freight and insurance.

The ICG secretariat (WHO) will issue an invoice within 30 days of shipment. The country or agency should transfer the funds within 30 days of reception of this invoice and in accordance with WHO administrative procedures and regulations.
## Standard Operating Procedures for Enhanced Meningitis Surveillance in Africa

### Analysis and Comments

Cumulative data by age groups

<table>
<thead>
<tr>
<th>Age groups</th>
<th>Cases</th>
<th>Deaths</th>
<th>% Population</th>
<th>Attack Rate</th>
<th>CFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-23 months</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2-4 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>5-14 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>15-29 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>30 years and over</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**TOTAL POPULATION:**

<table>
<thead>
<tr>
<th>Age groups</th>
<th>Cases</th>
<th>Deaths</th>
<th>% Population</th>
<th>Attack Rate</th>
<th>CFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-23 months</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2-4 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>5-14 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>15-29 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>30 years and over</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**TOTAL:**

<table>
<thead>
<tr>
<th>Age groups</th>
<th>Cases</th>
<th>Deaths</th>
<th>% Population</th>
<th>Attack Rate</th>
<th>CFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-23 months</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2-4 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>5-14 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>15-29 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>30 years and over</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

**Source of data:**

Peripheral level data (town, rural area, per health center zone,...) are requested to have a better picture and analysis of the situation to support the application (epidemic situation). This table should be completed with more details.

**Annex 1:** Epidemiological information

1. **Summary report on epidemiological situation**

Cumulative data by age groups

From: [Date]

To: [Date]

Place(s): [Location]

Source of data:

OUTBREAK OF MENINGOCOCCAL MENINGITIS

COMPLETE ONLYYELLOW CELLS

**ATTACK RATE PER AGE GROUP**

<table>
<thead>
<tr>
<th>Age groups</th>
<th>Cases</th>
<th>Deaths</th>
<th>% Population</th>
<th>Attack Rate</th>
<th>CFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-23 months</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2-4 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>5-14 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>15-29 years</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>30 years and over</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Districts</td>
<td>TOTAL Number done</td>
<td>Positive</td>
<td>DG Neg</td>
<td>Neisseria meningitidis</td>
<td>LATEX</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------</td>
<td>----------</td>
<td>--------</td>
<td>------------------------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A W135/Y Other* Spn Hib Other*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
</tr>
<tr>
<td></td>
<td>TOTAL</td>
<td>0 0 0 0 0 0 0 0 0 0 0 0 0</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>%</td>
<td></td>
<td>#DIV/0!</td>
<td>#DIV/0!</td>
<td>#DIV/0!</td>
<td>#DIV/0!</td>
</tr>
</tbody>
</table>

* Please, specify
## ANNEX 8: List of participants at the Workshop to update SOP(s)

<table>
<thead>
<tr>
<th>N°</th>
<th>NOM - PRENOM</th>
<th>FONCTION/ ADRESSE</th>
<th>TELEPHONE</th>
<th>ADRESSE E-MAIL</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Dr Mamoudou Harouna Djingarey</td>
<td>Point Focal MVP/ai IST/Ouaga</td>
<td>00226 70 26 27 54</td>
<td><a href="mailto:djingareym@bf.afro.who.int">djingareym@bf.afro.who.int</a></td>
</tr>
<tr>
<td>02</td>
<td>Dr Sylvestre Tiendrebeogo</td>
<td>Surveillance Officer MVP/IST/Ouaga Burkina Faso</td>
<td>00226 70 26 14 08</td>
<td><a href="mailto:tiendrebeogos@bf.afro.who.int">tiendrebeogos@bf.afro.who.int</a></td>
</tr>
<tr>
<td>03</td>
<td>Dr Michel Yao</td>
<td>Point Focal EHA IST/Ouaga Burkina Faso</td>
<td>00226 75 64 22 43</td>
<td><a href="mailto:yaom@bf.afro.who.int">yaom@bf.afro.who.int</a></td>
</tr>
<tr>
<td>04</td>
<td>Mr Clement Lingani</td>
<td>Data Manager MVP/IST/Ouaga Burkina Faso</td>
<td>00226 70 23 06 60</td>
<td><a href="mailto:linganic@bf.afro.who.int">linganic@bf.afro.who.int</a></td>
</tr>
<tr>
<td>05</td>
<td>Dr Jean Ludovic Kambou</td>
<td>Service de la surveillance épidémiologique, Burkina Faso</td>
<td>00226 70 26 12 20</td>
<td><a href="mailto:kambouludo@hotmail.com">kambouludo@hotmail.com</a></td>
</tr>
<tr>
<td>06</td>
<td>Mr Tarbangdo T Félix</td>
<td>Gestionnaire des données Ouagadougou, Burkina Faso</td>
<td>00226 70 22 48 95</td>
<td><a href="mailto:tarbarfelix@yahoo.fr">tarbarfelix@yahoo.fr</a></td>
</tr>
<tr>
<td>07</td>
<td>Pr. Ag Lassana Sangaré</td>
<td>Bactériologie – Virologie CHUYO Ouaga, Burkina Faso</td>
<td>00226 70 26 84 67</td>
<td><a href="mailto:sangarel@hotmail.com">sangarel@hotmail.com</a></td>
</tr>
<tr>
<td>08</td>
<td>Dr Etienne D. Traoré</td>
<td>DPC/OMS/Burkina Faso</td>
<td>00226 70 10 52 66</td>
<td><a href="mailto:traoree@bf.afro.who.int">traoree@bf.afro.who.int</a></td>
</tr>
<tr>
<td>09</td>
<td>Mr Idrissa Kamaté</td>
<td>Assistant Labo OMS/MDSC/Ouaga, Burkina Faso</td>
<td>00226 70 70 11 23</td>
<td><a href="mailto:kamatei@oncho.afro.who.int">kamatei@oncho.afro.who.int</a></td>
</tr>
<tr>
<td>10</td>
<td>Dr Chokki Félicité</td>
<td>PO Epidémies/urgences OOAS/Bobo Dioulasso</td>
<td>00226 71 28 54 36</td>
<td><a href="mailto:lalefel08@yahoo.fr">lalefel08@yahoo.fr</a></td>
</tr>
<tr>
<td>11</td>
<td>Dr Souley Rabi Maitournam</td>
<td>DSS/RE/MSP BP : 13378 Niger</td>
<td>00227 96 99 58 78</td>
<td><a href="mailto:mairabi@yahoo.fr">mairabi@yahoo.fr</a></td>
</tr>
<tr>
<td>12</td>
<td>Mme ABANI Aminata M. Kéita</td>
<td>Gestionnaire Données DSS/RE BP : 13378 Niger</td>
<td>00227 96 96 75 93</td>
<td><a href="mailto:aminatakeita95@yahoo.fr">aminatakeita95@yahoo.fr</a></td>
</tr>
<tr>
<td>13</td>
<td>Dr Djibo Saccou</td>
<td>CERMES/Niger</td>
<td>00227 21 79 07 91</td>
<td><a href="mailto:sdjibo@cermes.org">sdjibo@cermes.org</a></td>
</tr>
<tr>
<td></td>
<td>Name</td>
<td>Position/Contact</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>--------------------------</td>
<td>-----------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Dr Garba Soga</td>
<td>DPC/OMS/Niger 00227 20 75 20 39 <a href="mailto:sogag@ne.afro.who.int">sogag@ne.afro.who.int</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Dr Kandioura Touré</td>
<td>Responsable Surveillance Epidémiologique, Mali 00223 66 72 25 57 <a href="mailto:kandiouratoure@yahoo.fr">kandiouratoure@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Dr Seydou Diarra</td>
<td>Responsable Labo Mali 00223 76 46 87 29 <a href="mailto:seydsous@yahoo.fr">seydsous@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Dr Nonkon Mory Kéita</td>
<td>Data Manager/DNS/SE 00223 66 79 94 74 <a href="mailto:nmkeita63@yahoo.fr">nmkeita63@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Dr Massambou Sacko</td>
<td>DPC/OMS/Mali 00223 66 74 78 54 <a href="mailto:sackom@ml.afro.who.int">sackom@ml.afro.who.int</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Pr. Bréhima Koumaré</td>
<td>Consultant Facilitateur Principal Mali 00223 74 52 57 37 <a href="mailto:koumareb@hotmail.com">koumareb@hotmail.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Dr Honoré Sourou Bankole</td>
<td>Responsable National des Laboratoires, Bénin 00229 97 87 27 44 <a href="mailto:bahosour@yahoo.fr">bahosour@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Dr NEKOUA M’PO N’Koué Tatchienta</td>
<td>Responsable Surveillance Epidémiologique Bénin 00229 97 49 49 58 <a href="mailto:nekmpo62@yahoo.fr">nekmpo62@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Dr Badziklou Kossi</td>
<td>Responsable du LNR/MPE - INH Togo 00228 221 06 33 00228 994 52 00 <a href="mailto:badziklouk@yahoo.fr">badziklouk@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Dr Tamakloe Tsidi Agbékou</td>
<td>Responsable de la SIMR, Division Épidémiologie, Togo 00228 221 4194 00228 901 26 21 <a href="mailto:stantameklo@yahoo.fr">stantameklo@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Dr N’Guessan Konan Elvis Nezi</td>
<td>Surveillance Épidémiologique INHP Côte d’Ivoire 00225 07 55 34 68 <a href="mailto:elvisnezi@yahoo.fr">elvisnezi@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Pr. Kacou-N’Douba Adèle</td>
<td>CNR Meningites Côte d’Ivoire 00225 07 84 24 00 <a href="mailto:knadele@yahoo.fr">knadele@yahoo.fr</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Dr Tano-Bian Aka</td>
<td>DPC/OMS Côte d’Ivoire 00225 01 08 82 47 <a href="mailto:tanob@who.int">tanob@who.int</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Mr Kouadio Sié Kabran</td>
<td>Data Manager OMS Côte d’Ivoire 00225 22 51 72 62 00225 05 99 50 28 <a href="mailto:kouadios@who.int">kouadios@who.int</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Mr Yemi Gbadegesin</td>
<td>Lab. Officer in charge CSM, CPHL, Lagos, Nigeria 00234 80 386 48 107 <a href="mailto:gbadeyemi565@hotmail.com">gbadeyemi565@hotmail.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Dr Stéphane Hugonnet</td>
<td>GAR/HSE/HQ/OMS Genève 004122 791 10 55 <a href="mailto:hugonnets@who.int">hugonnets@who.int</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>